↓ Skip to main content

Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation

Overview of attention for article published in Molecular Pharmaceutics, April 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

8 tweeters


9 Dimensions

Readers on

17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation
Published in
Molecular Pharmaceutics, April 2018
DOI 10.1021/acs.molpharmaceut.8b00126
Pubmed ID

P. Jack Hoopes, Robert J. Wagner, Kayla Duval, Kevin Kang, David J. Gladstone, Karen L Moodie, Margaret Crary-Burney, Hugo Ariaspulido, Frank A. Veliz, Nicole F. Steinmetz, Steven N. Fiering


The presence and benefit of a radiation therapy-associated immune reaction is of great interest as the overall interest in cancer immunotherapy expands. Radiation therapy (RT) pathology studies have rarely demonstrated a consistent immune or inflammatory response following conventional RT. More recent information, primarily associated with the "abscopal effect", suggests a subtle radiation-based systemic immune response may be more common and have more therapeutic potential than previously believed. However, to be of consistent value the immune stimulatory potential of RT will clearly need to be supported by combination with other immunotherapy efforts. In this study, using a spontaneous canine oral melanoma model, we have assessed the efficacy and tumor immunopathology of two nanotechnology-based immune adjuvants combined with RT. The immune adjuvants were administered intratumorally, in an approach termed "in situ vaccination", that puts immunostimulatory reagents into a recognized tumor and utilizes the endogenous antigens in the tumor as the antigens in the antigen/adjuvant combination that constitutes a vaccine. The radiation treatment consisted of a local 6x6 Gy tumor regimen given over a 12-day period. The immune adjuvants were a plant-based virus-like nanoparticle (VLP) and a 110nm diameter magnetic iron oxide nanoparticle (mNPH)that was activated with an alternating magnetic field (AMF) to produce moderate heat (43°C/60 min). The RT was used alone or combined with one or both adjuvants. The VLP (4x200 µg) and mNPH (2x7.5 mg/gram tumor) were delivered intratumorally respectively during the RT regimen. All patients received a diagnostic biopsy and CT based 3-D radiation treatment plan prior to initiating therapy. Patients were assessed clinically 14-21 days post-treatment, monthly for 3 months following treatment and bimonthly, thereafter. Immunohistopathologic assessment of the tumors was performed before and 14-21 days following treatment. Results suggest that addition of VLPs and/or mNPH to a hypofractionated radiation regimen increases the immune cell infiltration in the tumor, extends the tumor control interval and has important systemic therapeutic potential.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 29%
Researcher 5 29%
Other 2 12%
Student > Master 2 12%
Student > Postgraduate 2 12%
Other 1 6%
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 4 24%
Medicine and Dentistry 4 24%
Unspecified 3 18%
Biochemistry, Genetics and Molecular Biology 2 12%
Agricultural and Biological Sciences 1 6%
Other 3 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2018.
All research outputs
of 13,415,438 outputs
Outputs from Molecular Pharmaceutics
of 2,530 outputs
Outputs of similar age
of 271,203 outputs
Outputs of similar age from Molecular Pharmaceutics
of 120 outputs
Altmetric has tracked 13,415,438 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,530 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,203 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 120 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.